Disease landscape
Lymphoma
In the Visegrad Group (V4) countries, a high level of limitations in the diagnosis and access to the latest treatment options for lymphomas was observed, as measured by the GAP scale. Results vary significantly across countries: the scores of Poland and the Czech Republic, at 51–57 points, are nearly twice as high as those of Hungary and Slovakia, at 26 and 30 points, respectively. The main driver of these GAP limitations in the V4 countries is the lack of reimbursement or significant reimbursement restrictions affecting most of the medicines included in the analysis, as well as a low, and in the case of Hungary and Slovakia zero or near-zero, proportion of patients treated with CAR-T therapies.
Cross-Country
General GAP for Lymphoma
Compliance with guidelines
Of the 30 medicines recommended in clinical practice guidelines, 16–17 are available to some extent in the Czech Republic and Poland (with guideline alignment above 50%), whereas in Slovakia and Hungary publicly funded access covers only 37% and 27% of all recommended therapies, respectively.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
car-t
Drug access
Number of patients treated (2024)
*registered in 2025
Drug access
POPULATION treated (%) with car-t
Main issues
- The average time to reimbursement for lymphoma drugs in the V4 countries is 3.6 years. The difference between the shortest and the longest mean time to reimbursement among the states is 1.3 years.
- The proportion of patients in the target population treated with CAR-T therapy is low, estimated at around 25% in Poland and 27% in the Czech Republic. In Hungary, the therapy was not available, while in Slovakia it was used in only a single patient.
- Disability adjusted life-years (DALY) burden in the V4 countries is about 10-15% lower than the EU average. As in the EU as a whole, the stabilization of burden was observed in the V4 countries in 2005-2019.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).